Decorative dot pattern background image.
Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image. Decorative blue shape background image.

GOG-3086 STRO-002-GM3

Trial Overview

Official Title

A Phase 2 Open-label Study Evaluating the Efficacy and Safety of Luveltamab Tazevibulin (STRO-002) in Women with Relapsed Platinum-resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) Expressing Folate Receptor alpha (FOLR1)

Study Purpose

To investigate the efficacy and safety of luveltamab tazevibulin in women with ovarian cancer (including fallopian tube or primary peritoneal cancers) expressing FOLR1.

Diagnosis

High-grade serous ovarian, primary peritoneal, or fallopian tube cancer.

Eligibility

Platinum resistant recurrent/persistent.  1-3 prior lines of therapy.  FOLR1>25%.

Intervention

Luveltamab tazevibulin IV every 3 weeks testing 2 different dose levels.

For more information, visit Clinicaltrials.gov

Key Participation Requirements
Trial Location(s)
Methodist Estabrook Cancer Center
Gender
Female
Age
18 and Older
Enrollment Status
Recruiting
Phase
Phase II
Methodist Health System Trial Code
GOG-3086